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Abstract
Background
The use of food supplements containing botanicals is increasing in European markets.
Although intended to maintain the health status, several cases of adverse effects to Plant
Food Supplements (PFS) have been described.
Objectives
To describe the self-reported adverse effects collected during the European PlantLIBRA
PFS Consumer Survey 2011–2012, with a critical evaluation of the plausibility of the symp-
tomatology reported using data from the literature and from the PlantLIBRA Poisons Cen-
ters' survey.
Subjects/Setting
From the total sample of 2359 consumers involved in the consumers' survey, 82 subjects
reported adverse effects due to a total of 87 PFS.
Results
Cases were self-reported, therefore causality was not classified on the basis of clinical evi-
dence, but by using the frequency/strength of adverse effects described in scientific papers:
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52 out of 87 cases were defined as possible (59.8%) and 4 as probable (4.6%). Considering
the most frequently cited botanicals, eight cases were due to Valeriana officinalis (garden
valerian); seven to Camellia sinensis (tea); six toGinkgo biloba (Maidenhair tree) and Paulli-
nia cupana (guarana). Most adverse events related to the gastrointestinal tract, nervous
and cardiovascular systems.
Conclusions
Comparing the data from this study with those published in scientific papers and obtained
by the PlantLIBRA Poisons Centers' survey, some important conclusions can be drawn:
severe adverse effects to PFS are quite rare, although mild or moderate adverse symptoms
can be present. Data reported in this paper can help health professionals (and in particular
family doctors) to become aware of possible new problems associated with the increasing
use of food supplements containing botanicals.
Introduction
The European Union (EU) Directive on Food Supplements (2002/46/EC) defines food supple-
ments (which include PFS): ‘‘. . .foodstuffs the purpose of which is to supplement the normal
diet and which are concentrated sources of nutrients or other substances with a nutritional or
physiological effect, alone or in combination, marketed in dose form, namely forms such as
capsules, pastilles, tablets, pills and other similar forms, sachets of powder, ampoules of liquids,
drop dispensing bottles and other similar forms of liquids and powders designed to be taken in
measured small quantities”. Their market is growing significantly both in Europe and the USA
[1]. Although there exists some overlap/confusion with traditional herbal medicinal products
[2], plant food supplements cannot be sold as having any diagnostic, preventative or therapeu-
tic properties; their role is only complementary to the diet.
The consumption of Plant Food Supplements (PFS) is usually estimated on the basis of mar-
ket data, and mainly from import/export of raw ingredients, but since botanicals are used in
both food and medicinal areas, the extrapolation to PFS is quite difficult [3]. Data on the use of
dietary supplements reported by consumers are very limited and normally include only those
products containing vitamins and minerals [4]; other available data come from studies relating
to complementary/traditional medicine [5].
To provide new data on PFS usage patterns, a survey was performed with consumers of PFS
in the framework of the European Project PlantLIBRA (n. 249159); it involved 2359 adults
from Finland, Germany, Italy, Romania, Spain and UK. The main results of the PlantLIBRA
PFS Consumer Survey (2011–2012) were published in 2014 [6]; the present paper deals with
the adverse effects self-reported by the consumers participating in the survey.
Adverse effects to PFS have been reported by several authors; most of the studies were: a)
case reports describing a specific acute event, or b) reviews of cases in a specific clinical area
(cardiovascular, gastrointestinal, etc.) [7–8]. A critical limitation of the information reported to
date in the scientific literature is a lack of assessment of causality; in other words, the strict
association between the intake of a specific plant and the clinical event is rarely demonstrated
by measuring biomarkers or by the de-challenge/re-challenge approach. On this basis, a sys-
tematic review of the data on adverse effects due to PFS/botanical ingredients, including mis-
identification and interactions of PFS/botanicals with pharmaceutical drugs or nutrients was
undertaken [9]. Data were collected for 66 botanicals, which are common ingredients of PFS;
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all papers were classified for causality according to the WHO guidelines [10] and grouped as
"certain, probable, possible and uncertain/unclassifiable events". Among the 492 papers
selected, 402 (81.7%) dealt with adverse effects due to the botanical as such or in a PFS, and 89
(18.1%) described interactions with conventional drugs. Misidentification was confirmed in
one case [9].
The aims of this paper are: 1) to identify the adverse effects reported by the European partic-
ipants in the PlantLIBRA PFS Consumer Survey, and 2) to critically evaluate the plausibility of
the symptomatology reported as being related to PFS.
Materials and Methods
The survey was conducted in 6 European countries (Finland, Germany, Italy, Romania, Spain
and the United Kingdom), and recruitment of participants occurred in 4 cities in each country.
In this study, "Botanical" means raw material and derived preparations made from plants,
algae, fungi or lichens (http://www.efsa.europa.eu/en/topics/topic/botanicals). The botanicals
to be included in the survey were clearly defined at the outset; PFS were defined as the "food-
stuffs the purpose of which is to supplement the normal diet and which are concentrated
sources of botanical preparations that have nutritional or physiological effect, alone or in com-
bination with vitamins, minerals and other substances which are not plant-based". Herbal rem-
edies, other medicinal products based on botanicals, herbal teas or juices were excluded [6].
In order to obtain a sample of 400 consumers/each country, approximately 2000 individuals
were screened per country (total number close to 2400) [6]. Eligible consumers completed a
detailed questionnaire on PFS usage, providing product/plant names, dosage forms, frequency
of use, reasons for use, adverse effects, places and patterns of purchase and information sources
on products. Data on a maximum of five different PFS for each consumer was recorded; when
PFS were more than 5, the inclusion was based on the frequency of use. Responders' sociode-
mographic data, including age, gender, level of education and employment status, as well as
height, weight and health-related lifestyle information, were also collected. Further details on
the survey have been reported previously [6]. The composition of each PFS was obtained from
the label, if at disposal, or by searching the PFS ingredients in the website of producers.
Regarding the collection of data on adverse effects, the following two questions were
included for each product:
1. Have you experienced any adverse effects while taking this product?
2. If yes, which one? (list of symptoms provided, with "other" as an option).
Ethical aspects
Approval of the survey protocols was obtained from four ethics committees: the Bioethics
Commission of the University of Barcelona, Spain; the Ethics Committee of the Università
degli Studi di Milano, Italy; the Ethical Committee of the Faculty of Medicine—Transilvania
University of Brasov, Romania; and the Coordinating Ethics Committee, Hospital District of
Helsinki and Uusimaa, Finland.
Approval of the survey by these four ethics Committees required submitting all survey
material to their members for evaluation. No ethical approval for the survey was needed in
Germany and the United Kingdom. Furthermore, the ethical aspects were considered in the
European Commission Consolidated Review Report dated 30th September 2013 and evaluated
as “ethical issues regarding the surveys have been handled appropriately”.
In all countries, informed consent was obtained from survey participants verbally after read-
ing the survey information sheet. The data were collected anonymously on paper
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questionnaires and then transferred to an electronic database; all responders were assigned an
ID number prior to data analyses.
Statistical analysis
All data were entered into the statistical package SPSS for Windows v. 18 (IBM Corporation,
Somers, NY, USA), which was used for analysis.
Results and Discussion
A total of 11783 consumers (5799 males and 6004 females) were screened during the PlantLI-
BRA survey, of which 2359 were considered eligible and included in the study. The number of
consumers per country and the percentage self-reporting adverse effects are listed in Table 1.
Considering the entire survey, the percentage of consumers, who reported adverse effects
was approximately 3.5%. Differences were observed between countries; the number of consum-
ers reporting adverse effects ranged between 5 and 6% of the total interviewed in three coun-
tries (Finland, Germany and Spain), while they were less numerous in Romania (2%), Italy
(1%) and the United Kingdom (0.3%).
There were no significant differences based on sex or age groups (Table 1 and Table 2).
The data collected on adverse effects are presented in Table 3. Details of each of the 82 cases
are recorded including:
• ID of the 82 consumers reporting adverse effects. ID 1–23 were from Finland, ID 24–45 from
Germany, ID 46–69 from Spain, ID 70–74 from Italy, ID 75–81 from Romania, ID 82 from
the United Kingdom. When a consumer reported adverse effects for two PFS, letters A and B
follows the ID;
Table 1. Consumers included in the PlantLIBRA PFS Consumer Survey and self-reporting adverse effects.
Country Number of consumers in the survey Number of consumers reporting adverse effects Percentage
Finland Total number 401 23 5.7
Males 193 10 5.2
Females 208 13 6.3
Germany Total number 398 22 5.5
Males 197 13 6.6
Females 201 9 4.5
Italy Total number 378 5 1.3
Males 187 2 1.1
Females 191 3 1.6
Romania Total number 400 7 1.8
Males 199 4 2.0
Females 201 3 1.5
Spain Total number 402 24 6.0
Males 174 9 5.2
Females 228 15 6.6
United Kingdom Total number 380 1 0.3
Males 191 1 0.5
Females 189 0 -
Total Total number 2359 82 3.5
Males 1141 39 3.4
Females 1218 43 3.5
doi:10.1371/journal.pone.0150089.t001
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• Age and gender;
• The botanical/s contained in the PFS associated with the reported adverse effect. For a more
precise identification, Latin names have been used but the corresponding common names
are reported in Table 4 (see table note for scientific sources);
• The daily dose and the period of intake;
• The reason for use reported by the consumer, i.e. the physiological effect expected by the
consumer;
• An assessment of the suitability of the botanical ingredient(s) present in the consumed PFS
for the condition used, based on what the literature says about these ingredients. The main
literature sources were the list of physiological effects published by the Italian Ministry of
Health [11] and the EMA website [12]. In specific cases, other scientific papers were cited;
• The general health status of the consumer. These data allow a better assessment of adverse
effect causality;
• Any reported simultaneous intake of conventional medicines and other food supplements;
these data allow the assessment of possible interactions;
• The adverse effects reported by the consumers;
• A judgement as to the likelihood of causality, according to previous scientific citations and
taking into consideration all available data.
Considering the suitability of the botanical product used in relation to the physiological
effect expected by the consumers, the choice was considered appropriate in 88% of cases. One
case (ID 4) was considered non pertinent and nine (ID 8, 11, 12, 18, 23, 33, 44, 57, 74) judged
as unlikely or with limited evidence. One consumer (ID 08) used a product containing 12
herbal ingredients, but only Citrus aurantium could claim to have tonic properties due to the
presence of active amines. None of the herbal ingredients present have any reported immune
activity [11–12].
Since all cases were self-reported, it was not possible to establish causality of adverse effects
on the basis of clinical evidence. The scientific literature was used to assess the likelihood of the
Table 2. Age of consumers included in the PlantLIBRA PFS Consumer Survey and of those reporting
adverse effects.
Country Consumers in the whole survey (m
±SD)
Consumers reporting adverse effects (m
±SD)
Finland 48.3±15.7 48.7±13.8
Germany 47.0±15.8 48.3±16.4
Italy 44.0±16.2 40.6±15.2
Romania 42.9±16.7 43.1±17.9
Spain 47.1±13.9 50.6±11.4
United
Kingdom
48.9±14.2 35.0a
Total 46.4±15.6 48.0±14.2
m±SD = mean±Standard Deviation
a no SD since only one consumer reported adverse effects
doi:10.1371/journal.pone.0150089.t002
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Table 3. Adverse effects reported by PlantLIBRA PFS Consumer Survey participants.
ID Age/
Gender
Botanical/s^ Dose
and
period
Reasons for
use
"Suitability" Present or
past main
health
problems
Conventional
drugs + FS
Adverse
effects
Causality
01 55/F Camellia
sinensis, Panax
ginseng
1/d x 2w Tonic Yes [11] Migraine Antihistaminics,
Corticosteroids,
Ibuprofen,
Roxithromycin
+ FO, PO, VM
Gastric
problems
Possible
worsening of
gastric side
effects of anti-
inﬂammatory
drugs
02 31/M Echinacea
angustifolia, E.
purpurea
2/d x 2w Immunity Yes [11–12] None No drug + AA, VM Gastric
problems
Possible [43–
44]
03 55/F Glycine max 1/d x 6m Menopause Yes [11] Allergy Antiallergic drugs
+ Vitamin D
Gastric
problems
Possible [45–
46]
04 36/F Gossypium spp.,
Zingiber
ofﬁcinale
2/d x 3m Neuralgia No Allergy/
asthma, joint/
bone pain
Budesonide,
Formoterol,
Salbutamol + FO, V
Gastric
problems
Possible [14;
47]
05 54/F Zingiber
ofﬁcinale
1/d x 24d Joints/bones Yes [11] HCHO Simvastatin + PO,
VM
Gastric
problems
Possible [14;
47]
06 72/F Echinacea
angustifolia, E.
purpurea,
3/d x 4d Immunity Yes [11–12] HCHO No drug + Vitamin
D
Gastric
problems
Possible [43–
44]
07 57/F Echinacea
angustifolia, E.
purpurea,
3/d x 3d Immunity Yes [11–12] Cancer No drug + FO, V Tachycardia Unlikely
08 44/F Achillea
millefolium,
Citrus aurantium,
Crataegus spp.,
Daucus carota,
Equisetum
arvense,
Foeniculum
vulgare, Fucus
vesiculosus
[alga], Hibiscus
rosa-sinensis,
Ribes nigrum,
Spinacia
oleracea,
Triticum spp.,
Urtica dioica
2/w x 1m Immunity,
tonic
Unlikely Migraine No drug + VM Gastric
problems
Unassessable
due to the
presence of
several
ingredients
09 53/F Arctium lappa,
Betula spp.,
Cichorium
intybus, Cynara
scolymus,
Filipendula
ulmaria,
Foeniculum
vulgare
2/d x 1m Detoxiﬁcation Yes [12] None No drug + AA, E,
FO, PO, PE, VM
Increased
diuresis
Possible due to
the presence of
diuretic
ingredients
[Betula spp.,
Arctium lappa]
[48–49]
10 61/M Equisetum
arvense
3/d x
12m
Hair/skin Yes [11] None No drug + FO, V Hair loss/
fragile nail
Possible due to
decreased level
of thiamine [50]
(Continued)
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Table 3. (Continued)
ID Age/
Gender
Botanical/s^ Dose
and
period
Reasons for
use
"Suitability" Present or
past main
health
problems
Conventional
drugs + FS
Adverse
effects
Causality
11 31/F Calendula
ofﬁcinalis, Citrus
sinensis,
Dunaliella salina
[alga], Glycine
max, Picea spp.
1/d x 6m Antioxidant Limited
evidence
[13]
None No drug + PO, VM Gastric
problems
Unassessable
due to the
presence of
several
ingredients
12 42/M Zingiber
ofﬁcinale
1/d x 1m Bodybuilding,
tonic
Unlikely [14] None No drug + AA Gastric
problems
Possible [14;
47]
13 35/M Camellia sinensis 2/d x 2m Immunity,
body weight,
tonic, HCHO
Yes [11] HCHO No drug + Vitamin
D, AA, FO
Insomnia
and nausea
Possible for the
content in
caffeine [51]
14 39/M Olea europaea
(olive oil)
1/d x 9m Immunity,
hair/skin,
tonic, mood,
joints/bones,
blood
circulation
Yes [11] Psoriasis No drug + FO, PE,
VM
Diarrhoea
and nausea
Possible—high
intake of olive
oil could
produce
laxative effect
[22]
15 72/F Oryza sativa
+ Monascus
purpureus
[fungus]
1/d x
12m
HCHO Yes [15–19] Asthma,
hypertension,
cancer,
depression,
joint/bone pain
Acetylsalicylic acid,
Amilodipine,
Lisinopril,
Pantoprazole + VM
Gastric
problems
Possible [51–
52] Possible
worsening of
gastric side
effects of anti-
inﬂammatory
drugs
16 46/M Oryza sativa
+ Monascus
purpureus
[fungus]
1/d x
12m
HCHO Yes [15–19] HCHO,
hypertension
Drugs for
hypertension + FO,
PO, VM
Increased
liver
enzymes
Possible [52–
53]
17A 70/M Oryza sativa
+ Monascus
purpureus
[fungus]
1/d x
11m
HCHO Yes [15–19] HCHO,
diabetes,
hearth
disease,
allergy,
depression
Acetylsalicylic acid,
Enapril, Loratadine,
Metoprolol,
Mometasone + E,
FO, PO, VM
Dry skin Unlikely [52–53]
17B Plantago
psyllium, Prunus
africana
1/d x 2m Urinary tract Yes [20] Gastric
problems
Possible [54]
Possible
worsening of
gastric side
effects of anti-
inﬂammatory
drugs
18 49/M Gossypium spp.,
Zingiber
ofﬁcinalis
1/d x 2m Sleeping,
joints/bones
Unlikely Muscle, joint/
bone pain
Glucosamine + VM Gastric
problems
Possible [14,
47]
19 68/F Oryza sativa
+ Monascus
purpureus
[fungus]
1/d x
12m
HCHO Yes [15–19] HCHO,
hypertension,
depression
Bisoprolol,
Olanzapine,
Thyroxin, Zopiclon
+ VM
Difﬁculty in
swallowing
Possible [55]
20 46/M Oryza sativa
+ Monascus
purpureus
[fungus]
1/d x 6m HCHO Yes [21–22] HCHO,
hypertension,
diabetes
Metformin,
Telmisartan + FO,
PO, VM
Increased
liver
enzymes
Possible [52–
53]
21 39/F Olea europaea,
Melissa ofﬁcinalis
1/d x 2w Immunity Yes [21–22] Migraine,
allergy
Enoxaparin+ PO,
VM
Allergic
symptoms
Possible [56]
(Continued)
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Table 3. (Continued)
ID Age/
Gender
Botanical/s^ Dose
and
period
Reasons for
use
"Suitability" Present or
past main
health
problems
Conventional
drugs + FS
Adverse
effects
Causality
22 24/M Camellia sinensis 1/d x 2m Immunity,
body weight,
tonic,
antioxidant
Yes [11–12] None No drug + E, FO,
PO, VM
Nausea Possible [57]
23 40/F Urtica dioica 3/d x 2m Body weight,
immunity
Limited
evidence
[23–24]
None No drug + AA, FO,
PO, VM
"Easy"
sweating
Possible [58]
24 48/F Arthrospira
platensis [alga]
1/d x 5m Antioxidant,
immunity
Yes [25–26] Migraine Analgesics + V Insomnia Uncertain
25 47/M Auricularia
auricula-judae
[fungus], Coffea
arabica, Fallopia
japonica/
Polygonum
cuspidatum,
Ginkgo biloba,
Panicum
miliaceum,
Polyporus
umbellatus
[fungus],
Saccharomyces
cerevisiae
[yeast], Serenoa
repens,
Trigonella
foenum-
graecum,
Ziziphus jujuba
2/d x
12m
Hair/skin,
energy
Yes [11, 27–
28]
HCHO None Discomfort Unassessable
due to the
presence of
several
ingredients
26 57/M Cucurbita
maxima,
Vaccinium
macrocarpon
2/d x 2m Urinary tract Yes [11] HCHO,
hypertension
Benazepril Discomfort Unassessable
27 45/M Saccharomyces
cerevisiae [yeast]
3/d x 3m Hair/skin Yes [29–30] None None Skin
problems
Unlikely
[Allergy?]
28 42/M Asparagus
ofﬁcinalis,
Cynara
scolymus,
Cichorium
intybus (inulin),
Plantago
psyllium
1/d x 2w Constipation Yes [11] None No drug + M Diarrhoea Possible [59]
29 64/F Nigella sativa 1/d x 1m Immunity,
HCHO
Yes [31–32] None No drug + M Mild
ﬂatulence
Unlikely
30 42/F Cynara scolymus 1/d x 6m Digestion,
HCHO
Yes [11–12] HCHO No drug + VM Nausea Possible [59]
31 62/F Glycine max 3/d x 3m Menopause Yes [11] Allergy No drug + FO, M Gastric
problems
Possible [45–
46]
32 31/M Matricaria
recutita, Melissa
ofﬁcinalis,
Valeriana
ofﬁcinalis
3/d x 6m Sleeping and
mood
problems
Yes [11–12] Migraine,
peptic ulcer,
sleep disorders
None Dizziness Possible [60]
(Continued)
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Table 3. (Continued)
ID Age/
Gender
Botanical/s^ Dose
and
period
Reasons for
use
"Suitability" Present or
past main
health
problems
Conventional
drugs + FS
Adverse
effects
Causality
33 56/M Brassica
oleracea
2/d x 2m Body weight Unlikely Hypertension,
sleeping
disorders,
chronic
bronchitis
None Gastric
problems
Unlikely
34 29/M Saccharomyces
cerevisiae [yeast]
2/d x 3m Hair/skin Yes [29–30] None None Gastric
problems,
diarrhoea
Unlikely
35A 64/F Cynara scolymus 1/d x 5d Body weight,
HCHO,
digestion
Yes [12] Hypertension,
asthma,
diabetes, joint/
bone pain
Beclometason
[spray], Formoterol
[spray], Metformin,
Thyroxin + VM, E
(lactase)
Diarrhoea Possible [22]
35B Camellia
sinensis,
Crataegus spp.,
Olea europaea
(olive oil),
Viscum album
Unknown Possible (olive
oil)
36 27/F Olea europaea
(olive oil)
1/d x 5w HCHO, body
weight,
digestion,
blood
circulation
Yes [11–12] HCHO No drug + FO, VM Diarrhoea Possible [22]
37 65/M Ginkgo biloba 4/w x
12m
Memory Yes [11–12] HCHO Iron
supplementation, V
Insomnia Possible [61]
38 66/F Ginkgo biloba 5/w x 6m Memory Yes [11–12] None None Constipation Possible [62]
39 23/M Paullinia cupana 1/d x 2m Energy Yes [11–12] None None Diarrhoea Unlikely
40 19/M Paullinia cupana 2/w x 3w Energy,
urinary tract
Yes [11–12] None None Constipation Unlikely
41 71/M Cynara scolymus 2/w x 4w Antioxidant,
immunity,
digestion
Yes [11–12] HCHO,
hypertension
Metopolol, Ramipril Gastric
problems
Possible [59]
42A 31/M Peumus boldus 2/w x 1w Digestion Yes [11–12] None None Constipation Unlikely
42B Linum
usitatissimum
2/w x 3w Digestion Yes [11–12] Diarrhoea Unlikely at the
dose used
43 66/F Panax ginseng 1/w x 6w HCHO,
relaxing, hair/
skin
Yes [33–34] HCHO,
cataract
None Constipation Possible [63]
44 66/M Olea europaea 5/w x 2w Hair/skin Unlikely None None Gastric
problems
Unlikely
45 41/F Oenothera
biennis
2/d X 3m Immunity,
hair/skin
Yes [11–12] Hypertension,
allergy
Antihypertensive
drugs, Thyroxin
Mild
eructation
Possible [64]
46 57/F Camellia
sinensis, Paullinia
cupana
2/d x 2m Body weight,
digestion,
energy/tonic
Yes [11–12,
35]
None No drug Insomnia Probable due to
the content in
caffeine [35]
47 43/F Cassia
angustifolia,
Illicium verum,
Raphanus sativus
var. niger,
Rhamnus
purshiana
1/d x 4w Body weight,
digestion
Yes [11] Hypertension,
migraine
No drug Diarrhoea Possible [65–
66]
(Continued)
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Table 3. (Continued)
ID Age/
Gender
Botanical/s^ Dose
and
period
Reasons for
use
"Suitability" Present or
past main
health
problems
Conventional
drugs + FS
Adverse
effects
Causality
48 47/F Rhamnus
purshiana
1/d x 9m Digestion Yes [11] Chronic
neutropenia,
glaucoma,
vascular
problems
Bimatoprost,
Timolol
Gastric
problems
Possible [66]
49 36M Valeriana
ofﬁcinalis
4/w x 5m Sleeping,
relaxing,
mood
Yes [11–12] None None Insomnia Unlikely but
described [67]
50 61/M Punica granatum 2/d x
12m
Prostate Yes [36] Cancer None Diarrhoea Possible for
high intake or
previous
intestinal
disorders [68]
51 46/F Cassia
angustifolia,
Raphanus sativus
var. niger
1/d x 2m Digestion Yes [11] None None Flatulence Possible [65]
52 69/F Pimpinella
anisum
2/d x
12m
Digestion Yes [11–12] Hypertension,
osteoporosis
Amlodipine Diarrhoea Uncertain
(associated with
allergic
reaction)
53 61/F Valeriana
ofﬁcinalis
2/d x
12m
Sleeping,
relaxing,
mood
Yes [11–12] HCHO, heart
disease,
muscles, joint/
bone pain,
cataract
Alprazolam,
Simvastatin
Constipation Possible—
abdominal
cramps have
been described
[69]
54 72/F Valeriana
ofﬁcinalis
1/d x 8m Sleeping,
memory,
relaxing
Yes [11–12] Cancer, joint/
bone pain
None Migraine Possible [67]
55 36/F Panax ginseng,
Paullinia cupana
1/d x 3m Energy/tonic Yes [11–12] None Birth-control pill Tachycardia Probable [70]
56 39/M Passiﬂora
incarnata
1/d x
10m
Sleeping,
relaxing
Yes [11–12] Fatigue;
insomnia
None Insomnia Unlikely
57 63/M Malus
domestica,
Citrus limon
2/d x 4m Constipation Unlikely HCHO, heart
disease,
hypertension
Quinapril/
Hydrochlorthiazide,
Diosmin/Esperidin
[ﬂavonoids]
Gastric
problems
Unlikely
58 50/F Paullinia cupana 1/d x 2w Energy/tonic Yes [11–12] Hypertension,
anxiety,
depression
Fluoxetine Tachycardia Probable [70]
59 49/F Valeriana
ofﬁcinalis
1/d x 3m Relaxing Yes [11–12] HCHO;
hypertension,
migraine,
allergy, anxiety
No drug + SI, VM Flatulence Possible—
abdominal
cramps have
been described
[69]
60 64/F Oenothera
biennis
3/d x 9m Breast nodule Yes [12] Hypertension,
allergy
Valsartan + AA, V,
SI
Cystitis Unlikely
61 60/F Harpagophytum
procumbens
3/d x 1m Joints/bones Yes [11–12] Bone/joint
pain, low back
pain
None Gastric
problems
Possible [71]
62 42/M Allium sativum 3/d x 2m Immunity Yes [37] Asthma, renal
problems
Amoxicillin/
clavulinic acid
Allergic
symptoms
Possible (quite
rare)
(Continued)
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Table 3. (Continued)
ID Age/
Gender
Botanical/s^ Dose
and
period
Reasons for
use
"Suitability" Present or
past main
health
problems
Conventional
drugs + FS
Adverse
effects
Causality
63 49/M Taraxacum
ofﬁcinale
3/d x 8m Digestion,
diuretic
Yes [11–12] Liver disease None Diarrhoea Unlikely
64 42/M Valeriana
ofﬁcinalis
2/d x 4m Sleeping,
relaxing
Yes [11–12] Liver disease,
gallbladder
inﬂammation
None Insomnia Unlikely but
described [67]
65A 38/F Equisetum
arvense
2/d x 4m Hair/skin,
urinary tract
Yes [11–12] Muscle and
bone pain,
migraine,
ulcer, anxiety
and
depression,
urinary
problems
Trimethoprim,
Sulfamethoxazol,
Ibuprofen
Constipation Possible—
gastrointestinal
complaints
have been
reported [72]
65B Taraxacum
ofﬁcinale
1/d x 4m Urinary tract Yes [11–12] Dizziness Unlikely even
though
described for
interaction with
acetylsalicylic
acid
66 46/F Lepidium meyenii 2/d x 3m Urinary tract
[kidney
stones]
Yes [38] Allergy, kidney
stones
Ibuprofen,
Metamizole,
Potassium citrate
Diarrhoea Unlikely
67 54/M Echinacea
angustifolia
3/d x 1m Flu cold Yes [12] HCHO,
hypertension
Metformin,
Olmesartan/
Medoxomil
Increased
glycemia
Unlikely
68 61/M Echinacea spp 1/d x 2m Sinusitis Yes (cold)
[12]
HCHO, anxiety
and
depression
Atorvastatin,
Enalapril
Gastric
problems
Possible [73]
69A 30/M Allium sativum 1/d x 3m Immunity, ﬂu
cold
Yes [37] Allergy None Gastric
problems
Possible [74]
69B Valeriana
ofﬁcinalis
2/d x
12m
Sleeping Yes [11–12] Allergy None Migraine Possible [67]
70 29/F Foeniculum
vulgare
3/d x 2m Body weight,
urinary tract
Yes [12] Asthma,
allergy
Beclometasone,
Drospirenone/
Ethinyl estradiol,
Salbutamol
Difﬁcult
swallowing
Possible since
reported in
cases of allergy
71 35/M Paullinia cupana 1d x 5m Energy/tonic,
mood
Yes [11–12] Heart disease None Dizziness Possible [75]
72 52/M Aloe
barbadensis,
Harpagophytum
procumbens
2d x 4w Joints/bones Yes [11–12] Muscle, bone/
joint pain
None Unspeciﬁed Unassessable
73 26/F Panax ginseng 1d x 2w Energy/tonic Yes [11–12] None No drug + Inositol,
folic acid
Tachycardia Possible [76]
74 61/F Cyamopsis
tetragonoloba
20/m x ? Body weight,
energy/tonic
Unlikely
[39–40]
Diabetes None Nausea Possible [40]
75 69/M Ginkgo biloba 2/d x ? Joints/bones,
blood
circulation
Yes [11] Diabetes, heart
disease,
hypertension,
liver disease,
stroke,
gallbladder
inﬂammation/
stones
Acenocumarole,
Captopril,
Trimetazidine
Insomnia Possible [77]
(Continued)
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adverse effects being associated with the botanical used and 56 out of 87 (64%) cases were
defined as possible (52) or probable (4) according to 1) the daily dose and period of intake, and
2) the frequency and strength of scientific evidence. The most significant references are
reported in Table 3. The association was not confirmed for 28 cases. The interaction with con-
ventional drugs was considered possible in three cases (ID 01, 15 and 17B). It is important to
underline that comparing the list of conventional drugs used with the column “present or past
main health problems”, there are several incongruences; this is due to the self-reported nature
of information collected.
The frequency of self-reported adverse effects in relation to each botanical is reported in
Table 4; the total number of botanical ingredients contained in PFS with reported adverse
effects was 72 and the total counts were 144. In most cases (46%), the PFS involved contained
one ingredient. Forty botanicals (55.6% of the total) were associated with a single adverse event
and 80% of them were included in PFS containing two or more ingredients. Considering the
Table 3. (Continued)
ID Age/
Gender
Botanical/s^ Dose
and
period
Reasons for
use
"Suitability" Present or
past main
health
problems
Conventional
drugs + FS
Adverse
effects
Causality
76 21/F Ginkgo biloba 1/d x ? Memory Yes [11] None No drug
+ Polyphenols
Dizziness Possible [78]
77 19/M Ginkgo biloba 2/d x 14d Memory Yes [11] Hypertension Captopril Insomnia Possible [77]
78 41/F Arthrospira
platensis [alga],
Hippophae
rhamnoides
1/d x ? Immunity,
energy/tonic
Yes [11] Anemia,
arrhythmia
None Gastric
problems,
nausea
Unlikely
79 50/M Camellia sinensis 1/d x 2w Immunity Yes [41] HCHO,
diabetes,
migraine
None Diarrhoea,
gastric
problems
(nausea)
Unlikely
80 49/M Camellia sinensis 1/d x 2w Immunity Yes [41] Migraine, ulcer None Diarrhoea,
gastric
problems
(nausea)
Unlikely
81 53/F Betula spp.,
Equisetum
arvense,
Juniperus
communis,
Pimpinella
anisum,
Vaccinium vitis-
idaea
3/d x 20d Urinary tract Yes [11] HCHO,
asthma,
diabetes, heart
disease,
hypertension,
liver disease,
chronic
bronchitis,
cataract,
osteoporosis,
allergy, cancer,
Basedow
disease
Enalapril,
Metformin,
Nicergoline,
Simvastatin
Gastric
problems
Unassessable
due to the
presence of
several
ingredients
82 35/M Aloe vera 3/w x
12m
Joints/bones Yes [42] None None Diarrhoea Probable
[laxative effect]
^ according to: for plants US Department of Agriculture (plants.usda.gov); for algae www.algaebase.org; for fungi www.indexfungorum.org
? unknown
AA= Supplement containing amino acids; FO= Fish Oil; E= Enzymes; HCHO= Hypercholesterolemia; M= Supplement containing minerals; PE=
Prebiotics; PO= Probiotics; SI= Soy isoﬂavones; V= Supplement containing vitamins; VM= Supplement containing vitamins and minerals; d= day; m=
month; w= week
doi:10.1371/journal.pone.0150089.t003
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Table 4. Botanical ingredients contained in PFS with reported adverse effects.
Latin name^ Common name^ Number of counts
Total for country TOTAL 1
INGa
2–3
ING
 4
ING
FI D IT RO SP UK
Valeriana ofﬁcinalis Garden valerian 1 7 8 7 1
Camellia sinensis Tea 3 1 2 1 7 4 2 1
Ginkgo biloba Maidenhair tree 3 3 6 5 1
Paullinia cupana Guarana 2 1 3 6 4 2
Cynara scolymus Globe artichoke 1 4 5 3 2
Echinacea angustifolia/purpurea Black Samson Echinacea/ Eastern purple
coneﬂower
3 2 5 5
Olea europaea Olive 2 3 5 3 1 1
Oryza sativa + Monascus
purpureus
Red rice 5 5 5
Panax ginseng Chinese ginseng 2 1 1 1 5 2 3
Equisetum arvense Field horsetail 2 1 1 4 2 2
Allium sativum Cultivated garlic 3 3 3
Foeniculum vulgare Sweet fennel 2 1 3 1 2
Glycine max Soybean 2 1 3 2 1
Saccharomyces cerevisiae Yeast 3 3 2 1
Aloe barbadensis/vera Barbados aloe 1 1 2 1 1
Arthrospira platensis Spirulina 1 1 2 1 1
Betula spp. Birch 1 1 2 2
Cassia angustifolia Alexandrian senna 2 2 1 1
Citrus aurantium Sour orange 2 2 2
Crataegus spp. Hawthorn 1 1 2 2
Cichorium intybus Chicory 1 1 2 2
Gossypium spp. Cotton 2 2 2
Harpagophytum procumbens Devil's claw 1 1 2 1 1
Melissa ofﬁcinalis Common balm 1 1 2 2
Oenothera biennis Common evening primrose 1 1 2 2
Pimpinella anisum Anise burnet saxifrage 1 1 2 1 1
Plantago psyllium Psyllium 1 1 2 1 1
Raphanus sativus var. niger Spanish black radish 2 2 1 1
Rhamnus purshiana Cascara buckthorn 2 2 1 1
Taraxacum ofﬁcinale Common dandelion 2 2 2
Urtica dioica Stinging nettle 2 2 1 1
Zingiber ofﬁcinale Garden ginger 2 2 1 1
Achillea millefolium Common yarrow 1 1 1
Arctium lappa Greater burdock 1 1 1
Asparagus ofﬁcinalis Garden asparagus 1 1 1
Auricularia auricula-judae Jew's ear 1 1 1
Brassica oleracea Cabbage 1 1 1
Calendula ofﬁcinalis Pot marigold 1 1 1
Citrus limon Lemon 1 1 1
Coffea arabica Arabian coffee 1 1 1
Cucurbita maxima Winter squash 1 1 1
Cyamopsis tetragonoloba Guar 1 1 1
(Continued)
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most prevalent botanicals associated with adverse effects, 14 were associated with 68 reported
adverse effects, representing the 47.2% of the total counts. In particular, eight were due to
Valeriana officinalis (seven of them in Spain), seven to Camellia sinensis, six to Ginkgo biloba
and six to Paullinia cupana.
The association of adverse effects with different organ systems is listed in Table 5.
Table 4. (Continued)
Latin name^ Common name^ Number of counts
Total for country TOTAL 1
INGa
2–3
ING
 4
ING
FI D IT RO SP UK
Daucus carota Carrot 1 1 1
Dunaliella salina "Green alga"* 1 1 1
Fallopia japonica Japanese knotweed 1 1 1
Filipendula ulmaria Queen of meadow 1 1 1
Fucus vesiculosus Bladder wrack 1 1 1
Hibiscus rosa-sinensis Shoeblackplant 1 1 1
Hippophae rhamnoides Seaberry 1 1 1
Illicium verum Staranise tree 1 1 1
Juniperus communis Common juniper 1 1 1
Lepidium meyenii Maca 1 1 1
Linum usitatissimum Common ﬂax 1 1 1
Malus domestica Apple 1 1 1
Matricaria recutita German chamomile 1 1 1
Nigella sativa Black cumin 1 1 1
Panicum miliaceum Proso millet 1 1 1
Passiﬂora incarnata Purple passionﬂower 1 1 1
Picea spp. Spruce 1 1 1
Peumus boldus Boldo 1 1 1
Polyporus umbellatus Umbrella polypore 1 1 1
Prunus africana Red stinkwood 1 1 2
Punica granatum Pomegranate 1 1 1
Ribes nigrum European blackcurrant 1 1 1
Serenoa repens Saw palmetto 1 1 1
Spinacia oleracea Spinach 1 1 1
Trigonella foenum-graecum Sicklefruit fenugreek 1 1 1
Triticum spp. Wheat 1 1 1
Vaccinium macrocarpon Cranberry 1 1 1
Vaccinum vitis idaea Cowberry/lingonberry 1 1 1
Viscum album European mistletoe 1 1 1
Ziziphus jujuba Common jujube 1 1 1
Total counts 48 42 6 12 35 1 144 66 28 50
Percentage of the total 33 29 4 8 24 0.7 100 45.8 19.4 34.7
^ according to: for plants US Department of Agriculture (plants.usda.gov); for algae www.algaebase.org; for fungi www.indexfungorum.org
* no common name
FI = Finland; D = Germany; IT = Italy; RO = Romania; SP = Spain; UK = Unided Kingdom
aING = Ingredients (number of botanicals contained in the product associated with the adverse effect)
doi:10.1371/journal.pone.0150089.t004
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Approximately 60% of adverse events were related to the gastrointestinal tract, distributed
between gastric problems (where nausea was the most reported symptom) and intestinal effects
(mainly diarrhoea).
The nervous system was the second most affected area with nine cases of insomnia, four of
dizziness and two of migraine; the cardiovascular system was reported in four cases of tachy-
cardia. The stimulating effects of botanicals containing caffeine can explain the insomnia and
tachycardia reported by consumers 13, 46, 55, and 58, but in other cases, the effects were unex-
pected. An example is the case of insomnia due to Valeriana officinalis (ID 49 and ID 64),
which is the opposite of the usual physiological effect, associated with this botanical [11–12].
Ginkgo biloba was involved in three cases of insomnia and one of dizziness.
Hair and skin were affected in three cases. A case of hair loss was reported by consumer 10,
taking Equisetum arvense 3 units/day for 12 months. This adverse effect could be associated
with the reported effect of E. arvense in reducing the bioavailability of thiamine after chronic
consumption [50]. On the other hand, the role of thiamine deficiency in hair loss has been
hypothesised but insufficiently documented [79]. Hepatotoxicity, defined as an increased level
of liver enzymes, was reported by two consumers using red rice (Oryza sativa fermented by the
fungusMonascus purpureus). Red rice is widely used in mild hypercholesterolemia, as a "natu-
ral" alternative to statins. Several side effects have been described in consumers using this ingre-
dient, such as headache, dizziness, heartburn, gas and digestive tract discomfort, and it should
be used cautiously by people suffering from liver disease and those at risk of it [52–53]. Aller-
gies to Allium sativum and to a PFS containingMelissa officinalis and Olea europaea were
reported by two consumers (ID 62 and ID 21, respectively).
A difficulty in swallowing was reported by a consumer (ID 19), using red rice to reduce
blood cholesterol. Even though this effect has not been previously associated with red rice,
there are some reports concerning the statins (having similar biological activity) for which the
impaired swallowing was considered among possible symptoms of muscle degeneration [55].
Table 6 compares the plants most prevalently involved in adverse effects as reported by the
PlantLIBRA project, in relation to: 1) data from the literature [9], 2) reports from Poisons Cen-
ters [80]; and finally from this study.
It is important to underline that the review from the literature did not separate cases due to
botanicals used as food supplements or traditional medicines as was the case in the other two
data reviews. Moreover, due to the very high number of botanicals in PFS, the review on the
scientific literature included "only" 66 among the most frequently consumed botanicals. The
Table 5. Distribution of adverse effects among the different organ systems.
System Number of reports Percentage of total
Gastrointestinal system 52 59.8
Nervous system 15 17.2
Cardiovascular system 4 4.6
Skin and hair 3 3.4
Hepatotoxicity 2 2.3
Urinary tract 2 2.3
Immune system (Allergy) 2 2.3
Other 7 8.0
Total 87a 100
a The total number of adverse effects reported is 87 since 5 out of 82 consumers complained about two
PFSs
doi:10.1371/journal.pone.0150089.t005
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lists of plants most reported by Poisons Centers and by the consumers' survey are similar, shar-
ing five out 13 botanicals; among them Valeriana officinalis (garden valerian) and Camellia
sinensis (tea) were in the first two positions. Moreover, a similar position in the ranking was
occupied by Paullinia cupana (guarana), Cynara scolymus (globe artichoke), and Panax gin-
seng (chinese ginseng).
Conclusions
The cases of adverse effects described here were self-reported and thus without any supporting
clinical evidence; the agreement with data published in scientific papers and in particular with
the survey performed by the PlantLIBRA project among Poisons Centers allows the following
conclusions:
1. As reported previously, severe adverse effects related to PFS are quite rare [80];
2. Mild or moderate adverse symptoms can be present but most of them do not require clinical
support;
3. Data reported in this paper confirm that some plants are more frequently involved in
adverse effects than others and can help family doctors, among other health professionals,
to become aware about the possible consequences of the increasing use of food supplements
containing botanicals;
4. This information could also be used to educate the public as to the possibility of adverse
effects associated with the consumption of these food supplements.
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